N
RNAC icon

NanoDimension’s Cartesian Therapeutics RNAC Stock Holding History

NanoDimension’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$6.21M Sell
126,251
-7,166
-5% -$394K 25.2% 2
2022
Q2 		$5.24M Buy
133,417
+11,820
+10% +$350K 17.16% 3
2022
Q1 		$4.49M Hold
121,597
– – 9.84% 4
2021
Q4 		$11.9M Buy
+121,597
New +$13.1M 10.66% 4

Other funds holding RNAC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

NanoDimension's RNAC Position: Q3 2022 in Review

NanoDimension reduced its Cartesian Therapeutics (RNAC) stake by 5.4% in Q3 2022, selling an estimated $394K and leaving 126,251 shares worth $6.21M. The position accounts for 25.2% of the portfolio, ranked #2.

NanoDimension first reported a position in RNAC in Q4 2021 and has held it in 4 quarters since. The position peaked at $11.9M in Q4 2021. 96 funds tracked by Wall St. Rank hold RNAC as of Q3 2022.

  • NanoDimension held 126,251 shares of Cartesian Therapeutics worth $6.21M as of Q3 2022.
  • NanoDimension sold 7,166 Cartesian Therapeutics shares in Q3 2022, an estimated $394K.
  • Cartesian Therapeutics made up 25.2% of NanoDimension's portfolio in Q3 2022, its #2 holding.
  • NanoDimension first reported a position in Cartesian Therapeutics in Q4 2021 and has held it in 4 quarters since.
  • NanoDimension's Cartesian Therapeutics position peaked at $11.9M in Q4 2021.
  • 96 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2022.

Based on NanoDimension's 13F filing for Q3 2022, filed 9 Nov 2022.